APPILI THERAPEUTICS

In The Global Race 
Against Infectious Diseases

Internal Innovation; Active In-Licensing.

Appili Therapeutics is proud to be at the forefront of global efforts to address serious infectious disease threats.

Our systematic approach to building a diverse pipeline provides investment opportunities that serve the needs of patients, payers, and clinicians. Our strategy centers on identifying unmet medical needs, rather than adhering to a specific platform or technology, and matching those needs with potential solutions in the marketplace. This approach provides financial stability and the opportunity to leverage a broad range of government and industry programs, as well as to develop transformative programs that can impact the fundamental treatment landscape for many types of infections.

Latest News

INVESTOR QUICK LINKS

VIDEO: Appili Therapeutics is well funded and working to combat infectious diseases

March 17, 2021
Appili Therapeutics to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference on Friday, March 19th
March 5, 2021
Drs. Scott Gottlieb, Syra Madad, and Josh Schimmer Examined Scientific Milestones and Public Health Challenges That Have Defined the Global Response to COVID-19, and Important Role Appili Still Has to Play During Appili Therapeutics’ Inaugural Fireside Chat
February 25, 2021
Appili Therapeutics to Host Drs. Scott Gottlieb and Syra Madad in Virtual Fireside Chat Discussing COVID-19: What We’ve Learned About Pandemic Responses, and Where We Go From Here
February 24, 2021
Appili Therapeutics to Present as Part of Canada’s Top Three Pitches at Biocom’s Global Life Science Partnering Conference Today